Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K L Hyrich

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Opinion in Rheumatology|September 14, 2001
Infectious agents in chronic rheumatic diseasesK L Hyrich, R D Inman
Rheumatology (Oxford, England)|May 18, 2006
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterK L Hyrich, K D Watson, A J Silman, et al.
Annals of the Rheumatic Diseases|July 10, 2004
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safetyK L Hyrich, A J Silman, K D Watson, et al.
Annals of the Rheumatic Diseases|May 7, 2010
Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics RegisterW G Dixon, K L Hyrich, K D Watson, et al.
Rheumatology (Oxford, England)|April 19, 2008
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drugK L Hyrich, M Lunt, W G Dixon, et al.
Arthritis and Rheumatism|July 27, 2006
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics RegisterW G Dixon, K Watson, M Lunt, et al.
Arthritis Care & Research|June 11, 2010
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics RegisterW G Dixon, K D Watson, M Lunt, et al.
Arthritis and Rheumatism|September 1, 2007
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics RegisterW G Dixon, K D Watson, M Lunt, et al.
Arthritis and Rheumatism|September 1, 2007
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studiesW G Dixon, D P M Symmons, M Lunt, et al.
Annals of the Rheumatic Diseases|October 27, 2009
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)W G Dixon, K L Hyrich, K D Watson, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Rheumatology|September 14, 2001
Infectious agents in chronic rheumatic diseasesK L Hyrich, R D Inman
Rheumatology (Oxford, England)|May 18, 2006
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterK L Hyrich, K D Watson, A J Silman, et al.
Annals of the Rheumatic Diseases|July 10, 2004
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safetyK L Hyrich, A J Silman, K D Watson, et al.
Annals of the Rheumatic Diseases|May 7, 2010
Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics RegisterW G Dixon, K L Hyrich, K D Watson, et al.
Rheumatology (Oxford, England)|April 19, 2008
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drugK L Hyrich, M Lunt, W G Dixon, et al.
Arthritis and Rheumatism|July 27, 2006
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics RegisterW G Dixon, K Watson, M Lunt, et al.
Arthritis Care & Research|June 11, 2010
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics RegisterW G Dixon, K D Watson, M Lunt, et al.
Arthritis and Rheumatism|September 1, 2007
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics RegisterW G Dixon, K D Watson, M Lunt, et al.
Arthritis and Rheumatism|September 1, 2007
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studiesW G Dixon, D P M Symmons, M Lunt, et al.
Annals of the Rheumatic Diseases|October 27, 2009
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)W G Dixon, K L Hyrich, K D Watson, et al.
Pageof 2